Cargando…
Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!
Liquid biopsy is a rapidly emerging field due to an increasing number of oncogenic drivers and a better understanding of resistance mechanisms to targeted therapies in non-small cell lung cancer (NSCLC). The sensitivity of the most widely used blood-based assays is, however, limited in particular in...
Autores principales: | Durin, Lucile, Pradines, Anne, Basset, Céline, Ulrich, Bryan, Keller, Laura, Dongay, Vincent, Favre, Gilles, Mazieres, Julien, Guibert, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698102/ https://www.ncbi.nlm.nih.gov/pubmed/33207539 http://dx.doi.org/10.3390/cells9112486 |
Ejemplares similares
-
Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages
por: Guibert, Nicolas, et al.
Publicado: (2020) -
Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
por: Guibert, Nicolas, et al.
Publicado: (2017) -
Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
por: Delahaye, Celia, et al.
Publicado: (2022) -
Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges
por: Ulrich, Bryan, et al.
Publicado: (2021) -
A closer look at non-decoupling D-Terms
por: Staub, Florian
Publicado: (2016)